Ask AI
Bill117th CongressFiled Feb 4, 2021Crime and Law Enforcement
S. 253

Cannabidiol and Marihuana Research Expansion Act

Bill journey · stage 1 of 5

Just introduced

Filed
Comm.
Floor
Both
Law

What it doesSummary passed senate (Mar 24, 2022)

Cannabidiol and Marihuana Research Expansion Act

This bill establishes a new, separate registration process to facilitate research on marijuana.

Specifically, the bill directs the Drug Enforcement Administration (DEA) to follow specified procedures to register (1) practitioners to conduct marijuana research, and (2) manufacturers to supply marijuana for the research.

The bill allows certain registered entities (including institutions of higher education, practitioners, and manufacturers) to manufacture, distribute, dispense, or possess marijuana or cannabidiol (CBD) for the purposes of medical research. Additionally, the bill directs the DEA to register manufacturers and distributors of CBD or marijuana for the purpose of commercial production of an approved drug that contains marijuana or its derivative.

Finally, the bill includes various other provisions, including provisions that

  • require the DEA to assess whether there is an adequate and uninterrupted supply of marijuana for research purposes;
  • prohibit the Department of Health and Human Services (HHS) from reinstating the interdisciplinary review process for marijuana research;
  • allow physicians to discuss the potential harms and benefits of marijuana and its derivatives (including CBD) with patients; and
  • require HHS, in coordination with the National Institutes of Health and relevant federal agencies, to report on the therapeutic potential of marijuana for various conditions such as epilepsy, as well as the impact on adolescent brains and on the ability to operate a motor vehicle.

What just happenedMar 28, 2022

Held at the desk.

Who’s behind it

Sen. Feinstein, Dianne [D-CA](D-CA)Sponsor
10 cosponsors5 D5 R
Read on Congress.gov
10cosponsors1committees10actions1amendments1related bills12subjects
  1. Mar 28, 2022FloorH15000

    Held at the desk.

  2. Mar 28, 2022FloorH14000

    Received in the House.

  3. Mar 28, 2022Floor

    Message on Senate action sent to the House.

  4. Mar 24, 2022Floor

    Passed Senate with an amendment by Unanimous Consent. (text of amendment in the nature of a substitute: CR S1781-1783)

  5. Mar 24, 2022Floor17000

    Passed/agreed to in Senate: Passed Senate with an amendment by Unanimous Consent.(text of amendment in the nature of a substitute: CR S1781-1783)

  6. Mar 24, 2022Floor

    Measure laid before Senate by unanimous consent. (consideration: CR S1784)

  7. Mar 24, 2022Discharge

    Senate Committee on the Judiciary discharged by Unanimous Consent.

    Judiciary Committee
  8. Mar 24, 2022Committee14500

    Senate Committee on the Judiciary discharged by Unanimous Consent.

    Judiciary Committee
  9. Feb 4, 2021IntroReferral

    Read twice and referred to the Committee on the Judiciary. (Sponsor introductory remarks on measure: CR S477-478)

    Judiciary Committee
  10. Feb 4, 2021IntroReferral10000

    Introduced in Senate

Passed SenateMar 24, 202255

Cannabidiol and Marihuana Research Expansion Act

This bill establishes a new, separate registration process to facilitate research on marijuana.

Specifically, the bill directs the Drug Enforcement Administration (DEA) to follow specified procedures to register (1) practitioners to conduct marijuana research, and (2) manufacturers to supply marijuana for the research.

The bill allows certain registered entities (including institutions of higher education, practitioners, and manufacturers) to manufacture, distribute, dispense, or possess marijuana or cannabidiol (CBD) for the purposes of medical research. Additionally, the bill directs the DEA to register manufacturers and distributors of CBD or marijuana for the purpose of commercial production of an approved drug that contains marijuana or its derivative.

Finally, the bill includes various other provisions, including provisions that

  • require the DEA to assess whether there is an adequate and uninterrupted supply of marijuana for research purposes;
  • prohibit the Department of Health and Human Services (HHS) from reinstating the interdisciplinary review process for marijuana research;
  • allow physicians to discuss the potential harms and benefits of marijuana and its derivatives (including CBD) with patients; and
  • require HHS, in coordination with the National Institutes of Health and relevant federal agencies, to report on the therapeutic potential of marijuana for various conditions such as epilepsy, as well as the impact on adolescent brains and on the ability to operate a motor vehicle.
Introduced in SenateFeb 4, 2021

Cannabidiol and Marihuana Research Expansion Act

This bill establishes a new, separate registration process to facilitate research on marijuana.

Specifically, the bill directs the Drug Enforcement Administration (DEA) to follow specified procedures to register (1) practitioners to conduct marijuana research, and (2) manufacturers to supply marijuana for the research.

The bill allows certain registered entities (including institutions of higher education, practitioners, and manufacturers) to manufacture, distribute, dispense, or possess marijuana or cannabidiol (CBD) for the purposes of medical research. Additionally, the bill directs the DEA to register manufacturers and distributors of CBD or marijuana for the purpose of commercial production of an approved drug that contains marijuana or its derivative.

Finally, the bill includes various other provisions, including provisions that

  • require the DEA to assess whether there is an adequate and uninterrupted supply of marijuana for research purposes;
  • prohibit the Department of Health and Human Services (HHS) from reinstating the interdisciplinary review process for marijuana research;
  • allow physicians to discuss the potential harms and benefits of marijuana and its derivatives (including CBD) with patients; and
  • require HHS, in coordination with the National Institutes of Health and relevant federal agencies, to report on the therapeutic potential of marijuana for various conditions such as epilepsy, as well as the impact on adolescent brains and on the ability to operate a motor vehicle.
Cannabidiol and Marihuana Research Expansion Act — Informed